A carregar...
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
Non‐small cell lung cancer (NSCLC) patients harboring EGFR sensitive mutations may benefit from treatment with EGFR TKIs. Osimertinib, which is an irreversible third‐generation EGFR TKI, has demonstrated a convincing efficacy, irrespective of whether it is used in first‐ or second‐line treatment. Th...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7952795/ https://ncbi.nlm.nih.gov/pubmed/33506568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13817 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|